Mito-LND (Synonyms: Mito-Lonidamine)
目录号: PL07326 纯度: ≥97%
Mito-LND (Mito-Lonidamine) 是一种具有口服活性的且靶向线粒体的氧化磷酸化 (oxidative phosphorylation (OXPHOS)) 抑制剂。Mito-LND 抑制线粒体生物能,刺激活性氧 (reactive oxygen species) 的形成,并诱导肺癌细胞自噬细胞死亡。
CAS No. :2361564-49-8
商品编号 规格 价格 会员价 是否有货 数量
PL07326-5mg 5mg ¥5625.00 请登录
PL07326-10mg 10mg ¥9322.00 请登录
PL07326-25mg 25mg ¥17680.00 请登录
PL07326-50mg 50mg ¥27323.00 请登录
PL07326-100mg 100mg ¥40181.00 请登录
PL07326-200mg 200mg 询价 询价
PL07326-500mg 500mg 询价 询价
PL07326-10mM*1mLinDMSO 10mM*1mLinDMSO ¥8213.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Mito-LND
英文名称
Mito-LND
英文别名
Mito-LND
Cas No.
2361564-49-8
分子式
C43H45BrCl2N3OP
分子量
801.62
包装储存
-20°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
产品详情
Mito-LND (Mito-Lonidamine) 是一种具有口服活性的且靶向线粒体的氧化磷酸化 (oxidative phosphorylation (OXPHOS)) 抑制剂。Mito-LND 抑制线粒体生物能,刺激活性氧 (reactive oxygen species) 的形成,并诱导肺癌细胞自噬细胞死亡。
生物活性
Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells.
性状
Solid
体外研究(In Vitro)
Mito-LND blocks lung cancer growth, migration, and invasion. Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC50 values of 0.74 μM and 0.69?μM, respectively.
Mito-LND inhibits mitochondrial complex I and II activities with IC50 values of 1.2 μM and 2.4?μM, respectively in H2030BrM3 cells.
Mito-LND (1?μM) increases ROS generation in H2030BrM3 lung cancer cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells.
Mito-LND (2?μM) decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling. has not independently confirmed the accuracy of these
体内研究(In Vivo)
Mito-LND (7.5?μmol/kg; oral gavage; 5 days per week; for 3 consecutive weeks) treatment markedly enhanced potency against both lung cancer progression and metastasis.
Mito-LND also decreases the rate of growth of A549 tumor xenografts.
Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
-20°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
参考文献
[1]. Gang Cheng, et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10(1):2205.
溶解度数据
In Vitro: DMSO : 50 mg/mL (62.37 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

相关产品

更多
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2